Literature DB >> 17549254

Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice.

Ken-ichi Aihara1, Hiroyuki Azuma, Masashi Akaike, Yasumasa Ikeda, Masataka Sata, Nobuyuki Takamori, Shusuke Yagi, Takashi Iwase, Yuka Sumitomo, Hirotaka Kawano, Takashi Yamada, Toru Fukuda, Takahiro Matsumoto, Keisuke Sekine, Takashi Sato, Yuko Nakamichi, Yoko Yamamoto, Kimihiro Yoshimura, Tomoyuki Watanabe, Takashi Nakamura, Akimasa Oomizu, Minoru Tsukada, Hideki Hayashi, Toshiki Sudo, Shigeaki Kato, Toshio Matsumoto.   

Abstract

Heparin cofactor II (HCII) specifically inhibits thrombin action at sites of injured arterial wall, and patients with HCII deficiency exhibit advanced atherosclerosis. However, the in vivo effects and the molecular mechanism underlying the action of HCII during vascular remodeling remain elusive. To clarify the role of HCII in vascular remodeling, we generated HCII-deficient mice by gene targeting. In contrast to a previous report, HCII(-/-) mice were embryonically lethal. In HCII(+/-) mice, prominent intimal hyperplasia with increased cellular proliferation was observed after tube cuff and wire vascular injury. The number of protease-activated receptor-1-positive (PAR-1-positive) cells was increased in the thickened vascular wall of HCII(+/-) mice, suggesting enhanced thrombin action in this region. Cuff injury also increased the expression levels of inflammatory cytokines and chemokines in the vascular wall of HCII(+/-) mice. The intimal hyperplasia in HCII(+/-) mice with vascular injury was abrogated by human HCII supplementation. Furthermore, HCII deficiency caused acceleration of aortic plaque formation with increased PAR-1 expression and oxidative stress in apoE-KO mice. These results demonstrate that HCII protects against thrombin-induced remodeling of an injured vascular wall by inhibiting thrombin action and suggest that HCII is potentially therapeutic against atherosclerosis without causing coagulatory disturbance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17549254      PMCID: PMC1878511          DOI: 10.1172/JCI27095

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  63 in total

Review 1.  Does heparin cofactor II modulate atherosclerosis and restenosis?

Authors:  Douglas M Tollefsen
Journal:  Circulation       Date:  2004-06-08       Impact factor: 29.690

2.  Heparin cofactor II: a new marker for pre-eclampsia.

Authors:  J Bellart; R Gilabert; L Cabero; J Fontcuberta; J Monasterio; R M Miralles
Journal:  Blood Coagul Fibrinolysis       Date:  1998-03       Impact factor: 1.276

3.  Regulation of vascular smooth muscle cell proliferation by nuclear factor-kappaB and its inhibitor, I-kappaB.

Authors:  S Hoshi; M Goto; N Koyama; K Nomoto; H Tanaka
Journal:  J Biol Chem       Date:  2000-01-14       Impact factor: 5.157

4.  Altered dermatan sulfate structure and reduced heparin cofactor II-stimulating activity of biglycan and decorin from human atherosclerotic plaque.

Authors:  R A Shirk; N Parthasarathy; J D San Antonio; F C Church; W D Wagner
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

5.  Stimulation of a vascular smooth muscle cell NAD(P)H oxidase by thrombin. Evidence that p47(phox) may participate in forming this oxidase in vitro and in vivo.

Authors:  C Patterson; J Ruef; N R Madamanchi; P Barry-Lane; Z Hu; C Horaist; C A Ballinger; A R Brasier; C Bode; M S Runge
Journal:  J Biol Chem       Date:  1999-07-09       Impact factor: 5.157

6.  Rapid changes in the exon/intron structure of a mammalian thrombin inhibitor gene.

Authors:  P B Kamp; H Ragg
Journal:  Gene       Date:  1999-03-18       Impact factor: 3.688

7.  Hereditary homozygous heparin cofactor II deficiency and the risk of developing venous thrombosis.

Authors:  P Villa; J Aznar; A Vaya; F España; F Ferrando; Y Mira; A Estellés
Journal:  Thromb Haemost       Date:  1999-09       Impact factor: 5.249

8.  Cloning and characterization of human protease-activated receptor 4.

Authors:  W F Xu; H Andersen; T E Whitmore; S R Presnell; D P Yee; A Ching; T Gilbert; E W Davie; D C Foster
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

9.  Anticoagulant dermatan sulfate proteoglycan (decorin) in the term human placenta.

Authors:  M A Delorme; L Xu; L Berry; L Mitchell; M Andrew
Journal:  Thromb Res       Date:  1998-05-15       Impact factor: 3.944

10.  Fgf10 is essential for limb and lung formation.

Authors:  K Sekine; H Ohuchi; M Fujiwara; M Yamasaki; T Yoshizawa; T Sato; N Yagishita; D Matsui; Y Koga; N Itoh; S Kato
Journal:  Nat Genet       Date:  1999-01       Impact factor: 38.330

View more
  13 in total

1.  Androgen receptor counteracts Doxorubicin-induced cardiotoxicity in male mice.

Authors:  Yasumasa Ikeda; Ken-ichi Aihara; Masashi Akaike; Takashi Sato; Kazue Ishikawa; Takayuki Ise; Shusuke Yagi; Takashi Iwase; Yuka Ueda; Sumiko Yoshida; Hiroyuki Azuma; Kenneth Walsh; Toshiaki Tamaki; Shigeaki Kato; Toshio Matsumoto
Journal:  Mol Endocrinol       Date:  2010-05-25

Review 2.  Genetic basis of atherosclerosis: insights from mice and humans.

Authors:  Ioannis M Stylianou; Robert C Bauer; Muredach P Reilly; Daniel J Rader
Journal:  Circ Res       Date:  2012-01-20       Impact factor: 17.367

3.  Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice.

Authors:  Cristina P Vicente; Li He; Douglas M Tollefsen
Journal:  Blood       Date:  2007-09-18       Impact factor: 22.113

4.  Heparin cofactor II, a serine protease inhibitor, promotes angiogenesis via activation of the AMP-activated protein kinase-endothelial nitric-oxide synthase signaling pathway.

Authors:  Yasumasa Ikeda; Ken-ichi Aihara; Sumiko Yoshida; Takashi Iwase; Soichiro Tajima; Yuki Izawa-Ishizawa; Yoshitaka Kihira; Keisuke Ishizawa; Shuhei Tomita; Koichiro Tsuchiya; Masataka Sata; Masashi Akaike; Shigeaki Kato; Toshio Matsumoto; Toshiaki Tamaki
Journal:  J Biol Chem       Date:  2012-08-17       Impact factor: 5.157

5.  Vascular dermatan sulfate regulates the antithrombotic activity of heparin cofactor II.

Authors:  Li He; Tusar K Giri; Cristina P Vicente; Douglas M Tollefsen
Journal:  Blood       Date:  2008-02-15       Impact factor: 22.113

6.  Heparin cofactor II in atherosclerotic lesions from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study.

Authors:  Jill C Rau; Carolyn Deans; Maureane R Hoffman; David B Thomas; Gray T Malcom; Arthur W Zieske; Jack P Strong; Gary G Koch; Frank C Church
Journal:  Exp Mol Pathol       Date:  2009-09-09       Impact factor: 3.362

7.  Unchecked thrombin is bad news for troubled arteries.

Authors:  Eric Camerer
Journal:  J Clin Invest       Date:  2007-06       Impact factor: 14.808

8.  Heparin Cofactor II: A Novel Plausible Link of Obesity and Diabetes with Thrombosis.

Authors:  Yutaka Hasegawa; Yasushi Ishigaki
Journal:  J Atheroscler Thromb       Date:  2017-08-10       Impact factor: 4.928

9.  Endothelial Nitric Oxide Synthase-Independent Pleiotropic Effects of Pitavastatin Against Atherogenesis and Limb Ischemia in Mice.

Authors:  Takeshi Mitsuhashi; Ryoko Uemoto; Kazue Ishikawa; Sumiko Yoshida; Yasumasa Ikeda; Shusuke Yagi; Toshio Matsumoto; Masashi Akaike; Ken-Ichi Aihara
Journal:  J Atheroscler Thromb       Date:  2017-06-06       Impact factor: 4.928

10.  The Role of Heparin Cofactor Ⅱ in the Regulation of Insulin Sensitivity and Maintenance of Glucose Homeostasis in Humans and Mice.

Authors:  Kiyoe Kurahashi; Seika Inoue; Sumiko Yoshida; Yasumasa Ikeda; Kana Morimoto; Ryoko Uemoto; Kazue Ishikawa; Takeshi Kondo; Tomoyuki Yuasa; Itsuro Endo; Masato Miyake; Seiichi Oyadomari; Toshio Matsumoto; Masahiro Abe; Hiroshi Sakaue; Ken-Ichi Aihara
Journal:  J Atheroscler Thromb       Date:  2017-05-15       Impact factor: 4.928

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.